Chromaffin cell transplantation for neuropathic pain after spinal cord injury: a report of two cases

Chen, Lin; Hao, Xi Shan; Xiao, Jiang; Zhang, Feng; Chen, Di; Huang, Hongyun

doi:10.2147/jn.s120173

Cited by 5 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of clinical studies concerning cell therapies with a positive outcome have led to the suggestion that combination cell therapies and/or certain transplantation approaches with rehabilitation can be more effective 107 , 123 , 128 – 130 , 136 , 138 – …”

Section: Provisionsmentioning

confidence: 99%

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

et al. 2018

Self Cite

View full text Add to dashboard Cite

Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.

show abstract

Section: Provisionsmentioning

confidence: 99%

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…0 represents extremely uncontrollable pain, one point represents severe pain that needs and responds to anesthetics, two points represents mild pain that responds to common painkillers, and three points represents no pain. The results showed that pain improved by an average of 1.2 points after OECs transplantation ( Chen et al, 2020 ). Another report is: a 72-year-old stroke patient with right limb sensory and functional impairment and pain for 8 years, 4-month fetal-derived OECs were transplanted into the patient’s brain (cell volume 1x10 10 /L -1 ).…”

Section: The Application Of Oecs In the Treatment Of Nppmentioning

confidence: 99%

Olfactory ensheathing cells and neuropathic pain

Liu

Wang

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Damage to the nervous system can lead to functional impairment, including sensory and motor functions. Importantly, neuropathic pain (NPP) can be induced after nerve injury, which seriously affects the quality of life of patients. Therefore, the repair of nerve damage and the treatment of pain are particularly important. However, the current treatment of NPP is very weak, which promotes researchers to find new methods and directions for treatment. Recently, cell transplantation technology has received great attention and has become a hot spot for the treatment of nerve injury and pain. Olfactory ensheathing cells (OECs) are a kind of glial cells with the characteristics of lifelong survival in the nervous system and continuous division and renewal. They also secrete a variety of neurotrophic factors, bridge the fibers at both ends of the injured nerve, change the local injury microenvironment, and promote axon regeneration and other biological functions. Different studies have revealed that the transplantation of OECs can repair damaged nerves and exert analgesic effect. Some progress has been made in the effect of OECs transplantation in inhibiting NPP. Therefore, in this paper, we provided a comprehensive overview of the biology of OECs, described the possible pathogenesis of NPP. Moreover, we discussed on the therapeutic effect of OECs transplantation on central nervous system injury and NPP, and prospected some possible problems of OECs transplantation as pain treatment. To provide some valuable information for the treatment of pain by OECs transplantation in the future.

show abstract

“…Nowadays, a number of neurorestorative strategies have been brought to clinical practice, resulting in benefit to patients and improvement of their quality of life [[9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21]]. Given the rapid advances in the field, the International Association of Neurorestoratology (IANR) and the Chinese Association of Neurorestoratology (CANR) are working together to propose the improved vision of the “Clinical Neurorestorative Therapeutic Guidelines for Spinal Cord Injury (IANR/CANR version 2019)” based on the released guidelines [22].…”

Section: Introductionmentioning

confidence: 99%

Clinical Neurorestorative Therapeutic Guidelines for Spinal Cord Injury (IANR/CANR version 2019)

Huang

Young

Skaper

et al. 2020

Journal of Orthopaedic Translation

Self Cite

View full text Add to dashboard Cite

Functional restoration after spinal cord injury (SCI) is one of the most challenging tasks in neurological clinical practice. With a view to exploring effective neurorestorative methods in the acute, subacute, and chronic phases of SCI, “Clinical Therapeutic Guidelines of Neurorestoration for Spinal Cord Injury (China Version 2016)” was first proposed in 2016 by the Chinese Association of Neurorestoratology (CANR). Given the rapid advances in this field in recent years, the International Association of Neurorestoratology (IANR) and CANR formed and approved the “Clinical Neurorestorative Therapeutic Guidelines for Spinal Cord Injury (IANR/CANR version 2019)”. These guidelines mainly introduce restoring damaged neurological structure and functions by varying neurorestorative strategies in acute, subacute, and chronic phases of SCI. These guidelines can provide a neurorestorative therapeutic standard or reference for clinicians and researchers in clinical practice to maximally restore functions of patients with SCI and improve their quality of life.The translational potential of this articleThis guideline provided comprehensive management strategies for SCI, which contains the evaluation and diagnosis, pre-hospital first aid, treatments, rehabilitation training, and complications management. Nowadays, amounts of neurorestorative strategies have been demonstrated to be benefit in promoting the functional recovery and improving the quality of life for SCI patients by clinical trials. Also, the positive results of preclinical research provided lots of new neurorestorative strategies for SCI treatment. These promising neurorestorative strategies are worthy of translation in the future and can promote the advancement of SCI treatments.

show abstract

Chromaffin cell transplantation for neuropathic pain after spinal cord injury: a report of two cases

Cited by 5 publications

References 24 publications

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Olfactory ensheathing cells and neuropathic pain

Clinical Neurorestorative Therapeutic Guidelines for Spinal Cord Injury (IANR/CANR version 2019)

Contact Info

Product

Resources

About